Trials registration: ClinicalTrials.gov NCT00783094.
Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension
Version of Record online: 1 MAR 2012
© 2012 Wiley Publishing Asia Pty Ltd
LUTS: Lower Urinary Tract Symptoms
Volume 4, Issue 3, pages 110–119, September 2012
How to Cite
TAKEDA, M., NISHIZAWA, O., IMAOKA, T., MORISAKI, Y. and VIKTRUP, L. (2012), Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12-week Placebo-controlled Dose-finding Study with a 42-week Open-label Extension. LUTS: Lower Urinary Tract Symptoms, 4: 110–119. doi: 10.1111/j.1757-5672.2012.00144.x
- Issue online: 9 SEP 2012
- Version of Record online: 1 MAR 2012
- Received 9 October 2011; revised 8 December 2011; accepted 15 January 2012.
- benign prostatic hyperplasia;
- lower urinary tract symptoms;
- phosphodiesterase type 5 inhibitors;
Objectives: To examine the efficacy, safety, and dose response of tadalafil once daily in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS).
Methods: Men ≥45 years with moderate-to-severe BPH-LUTS were randomized to once-daily placebo (N = 140), tadalafil 2.5 mg (N = 142), or tadalafil 5.0 mg (N = 140), in a 12-week double-blind phase, followed by a 42-week, tadalafil 5.0 mg open-label extension (OLE) phase (N = 394). The primary outcome was total International Prostate Symptom Score (IPSS) change from baseline to last available observation in the double-blind phase.
Results: The least squares (LS) mean difference between placebo and tadalafil in total IPSS change from baseline was −0.7 (P = 0.201) and −1.1 (P = 0.062) for tadalafil 2.5 and 5 mg, respectively (ANCOVA; a dose-dependent improvement in placebo-adjusted total IPSS for tadalafil 5 mg versus 2.5 mg of 57%). Repeated-measures analyses identified a significant total IPSS change for tadalafil 5 mg (LS mean difference between placebo and tadalafil 5 mg: −1.2; P = 0.035), but not tadalafil 2.5 mg, at week 12. Significant improvements for tadalafil 5 mg were demonstrated (ANCOVA) for IPSS obstructive subscore (P = 0.033) and IPSS quality of life index (P = 0.022). Numerical improvements in IPSS scores were maintained over the OLE phase. Tadalafil was well tolerated with no unexpected adverse events.
Conclusion: Tadalafil (5.0 mg) had a favorable benefit-to-risk profile, supporting further investigation of tadalafil (5.0 mg) in Japanese men with BPH-LUTS.